Cognition Therapeutics announced that its Phase 2 START Study for Alzheimer’s disease has surpassed 50% enrollment. The study, conducted in partnership with the Alzheimer’s Clinical Trials Consortium (ACTC), is investigating the efficacy of zervimesine (CT1812) and is backed by an $81 million grant from the National Institute of Aging (NIA). This milestone signifies strong interest in a novel oral treatment targeting amyloid in early-stage Alzheimer’s.
Reaching this enrollment milestone is crucial, particularly given the significant unmet need for effective Alzheimer’s treatments. The substantial NIA funding underscores the study’s potential scientific impact. The high enrollment rate also suggests considerable patient and physician interest in zervimesine’s novel mechanism of action, potentially differentiating it from existing therapies. This enthusiasm reflects the urgent demand for new treatment strategies for Alzheimer’s, a devastating disease affecting millions.
The START study aims to enroll 540 participants with mild Alzheimer’s across approximately 50 US sites. Participants will receive either zervimesine or a placebo for 18 months. The study focuses on individuals with mild cognitive impairment and elevated amyloid levels, potentially representing an optimal patient population for zervimesine based on prior research. Previous Phase 2 SHINE study data indicated that zervimesine slowed cognitive decline by 38% compared to placebo, with even greater benefit observed in patients with lower p-tau217 levels, a biomarker for neuronal loss.
The progress of the START study holds significant implications for the future of Alzheimer’s treatment. Positive results could validate zervimesine’s unique approach and pave the way for a new class of oral therapies targeting amyloid. The study’s focus on early-stage Alzheimer’s is particularly important, as earlier intervention could potentially delay or prevent disease progression. This development carries substantial promise for patients, caregivers, and the healthcare industry as a whole.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
